MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Pfizer

Open

SectorGezondheidszorg

22.84 0.53

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

22.5

Max

22.85

Belangrijke statistieken

By Trading Economics

Inkomsten

-4.1B

411M

Verkoop

63M

18B

K/W

Sectorgemiddelde

15.631

57.333

EPS

0.63

Dividendrendement

7.8

Winstmarge

2.314

Werknemers

81,000

EBITDA

-4.3B

2.5B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+22.04% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

7.80%

2.63%

Volgende Winsten

29 apr 2025

Volgende dividenddatum

13 jun 2025

Volgende Ex Dividend datum

9 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-26B

126B

Vorige openingsprijs

22.31

Vorige sluitingsprijs

22.84

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Pfizer Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 apr 2025, 11:09 UTC

Belangrijke Marktbewegers

Pfizer Shares Slip After Company Scraps Weight-Loss Pill

9 apr 2025, 18:18 UTC

Belangrijke Marktbewegers

Pharma Shares Reverse Losses After Tariff Pause

9 apr 2025, 09:39 UTC

Belangrijke Marktbewegers

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

19 mrt 2025, 07:34 UTC

Acquisities, Fusies, Overnames

Pfizer Sells Remaining 7.3% Haleon Shareholding for $3.25 Billion

18 mrt 2025, 17:26 UTC

Acquisities, Fusies, Overnames

Pfizer to Dispose of Remaining Shareholding in Haleon

14 apr 2025, 14:36 UTC

Top Nieuws

Pfizer Halts Development of Weight-Loss Pill -- Update

14 apr 2025, 14:14 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Viking Seen as Potential Ticket To Get Pfizer Back Into Obesity Game -- Market Talk

14 apr 2025, 10:45 UTC

Top Nieuws

Pfizer Halts Development of Weight-Loss Pill -- WSJ

8 apr 2025, 21:26 UTC

Winsten

Pfizer Stock's Fall to '97 Level Lifts Yield Near 8%. Dividend Looks Safe. -- Barrons.com

26 mrt 2025, 22:29 UTC

Top Nieuws

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- 2nd Update

26 mrt 2025, 19:19 UTC

Top Nieuws

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- Update

26 mrt 2025, 17:39 UTC

Top Nieuws

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- WSJ

18 mrt 2025, 16:58 UTC

Acquisities, Fusies, Overnames

Haleon Intends to Cancel Purchased Ordinary Shares

18 mrt 2025, 16:57 UTC

Acquisities, Fusies, Overnames

Citigroup: Off-Market Transaction Will Close at Same Time as or Following Settlement of Offering

18 mrt 2025, 16:56 UTC

Acquisities, Fusies, Overnames

Citigroup: Off-Market Purchase Worth Approx GBP170M in Ordinary Shares

18 mrt 2025, 16:56 UTC

Acquisities, Fusies, Overnames

Citigroup: Haleon Agreed to Carry out Off-Market Purchase From Pfizer

18 mrt 2025, 16:52 UTC

Acquisities, Fusies, Overnames

Haleon Takes Note of Announcement

18 mrt 2025, 16:50 UTC

Acquisities, Fusies, Overnames

Citigroup: Haleon Won't Receive Any Net Proceeds From Offering

18 mrt 2025, 16:50 UTC

Acquisities, Fusies, Overnames

Citigroup: This Is Subject to Customary Closing Conditions

18 mrt 2025, 16:50 UTC

Acquisities, Fusies, Overnames

Citigroup: Pfizer Will Receive All of Net Proceeds From Offering

18 mrt 2025, 16:49 UTC

Acquisities, Fusies, Overnames

Citigroup: Bookbuilding Period May Close at Any Time on Short Notice

18 mrt 2025, 16:49 UTC

Acquisities, Fusies, Overnames

Citigroup: Bookbuilding Period Will Commence Immediately

18 mrt 2025, 16:49 UTC

Acquisities, Fusies, Overnames

Citigroup: Price Per Sale Share to Be Determined Through Accelerated Bookbuilding Process

18 mrt 2025, 16:48 UTC

Acquisities, Fusies, Overnames

Citigroup: Pfizer Intends to Sell Ordinary Shares to Institutional Investors

18 mrt 2025, 16:47 UTC

Acquisities, Fusies, Overnames

Citigroup:: Amount Is Pfizer's Entire Residual Shareholding in Haleon

18 mrt 2025, 16:47 UTC

Acquisities, Fusies, Overnames

Citigroup: This Represents Approx 7.3% Stake in Haleon

18 mrt 2025, 16:46 UTC

Acquisities, Fusies, Overnames

Citigroup: Pfizer Intends to Sell Approx 662M Ordinary Shares in Haleon

17 mrt 2025, 09:00 UTC

Top Nieuws

Pfizer Has a New Playbook for Reviving Sales -- And It's Starting to Pay Off -- WSJ

28 feb 2025, 12:00 UTC

Top Nieuws

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

14 feb 2025, 11:38 UTC

Top Nieuws
Winsten

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

Peer Vergelijking

Prijswijziging

Pfizer Prognose

Koersdoel

By TipRanks

22.04% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 27.8 USD  22.04%

Hoogste 32 USD

Laagste 23 USD

Gebaseerd op 17 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pfizer - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

17 ratings

5

Buy

12

Hold

0

Sell

Technische score

By Trading Central

22.12 / 23.055Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Very Strong Bearish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.